Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1998 1
1999 2
2001 4
2002 3
2003 2
2011 2
2012 1
2013 1
2015 1
2016 2
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
CD123 (interleukin 3 receptor alpha chain).
Moretti S, Lanza F, Dabusti M, Tieghi A, Campioni D, Dominici M, Castoldi GL. Moretti S, et al. Among authors: dabusti m. J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):98-100. J Biol Regul Homeost Agents. 2001. PMID: 11388753 Review. No abstract available.
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia.
Cavallari M, Cavazzini F, Bardi A, Volta E, Melandri A, Tammiso E, Saccenti E, Lista E, Quaglia FM, Urso A, Laudisi M, Menotti E, Formigaro L, Dabusti M, Ciccone M, Tomasi P, Negrini M, Cuneo A, Rigolin GM. Cavallari M, et al. Among authors: dabusti m. Oncotarget. 2018 Sep 28;9(76):34398-34412. doi: 10.18632/oncotarget.26146. eCollection 2018 Sep 28. Oncotarget. 2018. PMID: 30344950 Free PMC article. Review.
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.
Martinelli S, Cuneo A, Formigaro L, Cavallari M, Lista E, Quaglia FM, Ciccone M, Bardi A, Volta E, Tammiso E, Saccenti E, Sofritti O, Daghia G, Negrini M, Dabusti M, Tomasi P, Moretti S, Cavazzini F, Rigolin GM. Martinelli S, et al. Among authors: dabusti m. Mediterr J Hematol Infect Dis. 2016 Oct 15;8(1):e2016047. doi: 10.4084/MJHID.2016.047. eCollection 2016. Mediterr J Hematol Infect Dis. 2016. PMID: 27872727 Free PMC article. Review.
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients.
Cavazzini F, Rizzotto L, Sofritti O, Daghia G, Cibien F, Martinelli S, Ciccone M, Saccenti E, Dabusti M, Elkareem AA, Bardi A, Tammiso E, Cuneo A, Rigolin GM. Cavazzini F, et al. Among authors: dabusti m. Leuk Lymphoma. 2012 Jan;53(1):83-8. doi: 10.3109/10428194.2011.606384. Epub 2011 Sep 13. Leuk Lymphoma. 2012. PMID: 21767243
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA. Efficace F, et al. Among authors: dabusti m. Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12. Blood. 2011. PMID: 21750313 Free article.
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F. Efficace F, et al. Among authors: dabusti m. Leukemia. 2013 Jul;27(7):1511-9. doi: 10.1038/leu.2013.51. Epub 2013 Feb 18. Leukemia. 2013. PMID: 23417029
21 results